Bacteriophage Therapy for Clinical Biofilm Infections: Parameters That Influence Treatment Protocols and Current Treatment Approaches

• Published in: Antibiotics (Basel) Vol. 9; no. 11; p. 799
• Main Author: Doub, James B
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 12-11-2020; MDPI
• Subjects: Antibiotics; Bacteria; Bacterial infections; bacteriophage therapy; Bacteriophages; biofilm; Biofilms; Enzymes; Extracellular matrix; Hardware; hardware infections; Health aspects; Infections; left ventricular assist devices; Metabolism; Microbial mats; Morbidity; Parameters; Phages; prosthesis related infections; Therapy; United States; left ventricular assist devices; prosthesis related infections; bacteriophage therapy; hardware infections; biofilm
• ISSN: 2079-6382; 2079-6382
• DOI: 10.3390/antibiotics9110799

Biofilm infections are extremely difficult to treat, which is secondary to the inability of conventional antibiotics to eradicate biofilms. Consequently, current definitive treatment of biofilm infections requires complete removal of the infected hardware. This causes significant morbidity and mortality to patients and therefore novel therapeutics are needed to cure these infections without removal of the infected hardware. Bacteriophages have intrinsic properties that could be advantageous in the treatment of clinical biofilm infections, but limited knowledge is known about the proper use of bacteriophage therapy in vivo. Currently titers and duration of bacteriophage therapy are the main parameters that are evaluated when devising bacteriophage protocols. Herein, several other important parameters are discussed which if standardized could allow for more effective and reproducible treatment protocols to be formulated. In addition, these parameters are correlated with the current clinical approaches being evaluated in the treatment of clinical biofilm infections.